List of New Drugs approved in the year 2025 till date

S.No.	Name of New Drug	Indication	Date of Approval
1.	Tafamidis Bulk Drug	Not applicable as it is a bulk drug	16.01.2025
2.	Letermovir Bulk Drug &Letermovir Tablets 240mg and 480 mg	Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). It is also indicated for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative[D+/R-])	17.01.2025
3.	Fexuprazan hydrochloride Bulk Drug and Fexuprazan hydrochloride Tablets 40mg	Indicated for the treatment of erosive esophagitis(EE).	10.02.2025
4.	Edoxaban Tosylate Monohydrate Bulk Drug	Not applicable as it is a bulk drug	11.02.2025
5.	Edoxaban Tablets 15mg, 30mg and 60mg	In prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack(TIA). For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults.	20.02.2025
6.	Sodium Zirconium Cyclosilicate powder for Oral Suspension (LOKELMA) 5g/10g	Indicated for the treatment of Hyperkalaemia in adult patients.	05.03.2025
7.	Rimegepant Oral disintegrating tablets (ODT) 75 mg	For Acute treatment of migraine with or without aura in adults with a previous insufficient response to triptans.	27.03.2025
8.	Doravirine Bulk Drug and Doravirine Tablets 100mg	patients weighing at least 35 kg with no prior antiretroviral treatment history only(treatment naïve)	28.03.2025
9.	Tucatinib hemiethanolate bulk drug & Tucatinib tablets 50 mg and 150 mg	Indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.	08.04.2025
10.		It is indicated for the treatment of adult patients with: 1. Mantle cell lymphoma (MCL) who have received at least one prior therapy.	

11.	Linaclotide Bulk Drug &	 Waldenstrom's macrogloubulinemia (WM) Relapsed or refractory marginal zone lymphoma(MZL) who have received at least one anti-CD20-based regimen. Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma(SLL). Relapsed or refractory follicular lymphoma (FL),in combination with obinutuzumab, after two or more lines of systemic therapy. Indicated in adults for the treatment of Chronic	08.04.2025
	Linaclotide Capsule 72 mcg & Linaclotide Capsule 145 mcg	idiopathic constipation.	21.04.2025
12.	Drug & Siponimod Tablets 0.25 mg/1mg/2mg	For the treatment of patients with secondary progressive multiple sclerosis (SPMS) with active disease as evidenced by relapses or imaging features of inflammatory activity.	00.05.0005
	Ivosidenib 250 mg film coated tablet	 In combination with Azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia(AML) with an isocitrate dehydrogenase-1(IDH1) R132 mutation who are not eligible to receive standard Induction chemotherapy. As a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. 	
14.	Tegoprazan Tablet 50 mg	 Indicated for: Erosive Gastroesophageal Reflux Disease Non-erosive Gastroesophageal Reflux Disease Gastric Ulcer 	28.05.2025